Dworok, V.; Hähnel, V.; Bannehr, M.; Paar, V.; Edlinger, C.; Lichtenauer, M.; Butter, C.; Haase-Fielitz, A.
Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure—A Prospective Observational Study. J. Clin. Med. 2023, 12, 7200.
https://doi.org/10.3390/jcm12237200
AMA Style
Dworok V, Hähnel V, Bannehr M, Paar V, Edlinger C, Lichtenauer M, Butter C, Haase-Fielitz A.
Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure—A Prospective Observational Study. Journal of Clinical Medicine. 2023; 12(23):7200.
https://doi.org/10.3390/jcm12237200
Chicago/Turabian Style
Dworok, Victoria, Valentin Hähnel, Marwin Bannehr, Vera Paar, Christoph Edlinger, Michael Lichtenauer, Christian Butter, and Anja Haase-Fielitz.
2023. "Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure—A Prospective Observational Study" Journal of Clinical Medicine 12, no. 23: 7200.
https://doi.org/10.3390/jcm12237200
APA Style
Dworok, V., Hähnel, V., Bannehr, M., Paar, V., Edlinger, C., Lichtenauer, M., Butter, C., & Haase-Fielitz, A.
(2023). Soluble Suppression of Tumorigenicity 2 (sST2) in Patients with Predominantly Decompensated Right Heart Failure—A Prospective Observational Study. Journal of Clinical Medicine, 12(23), 7200.
https://doi.org/10.3390/jcm12237200
